147 related articles for article (PubMed ID: 15504971)
1. Phloridzin improves hyperglycemia but not hepatic insulin resistance in a transgenic mouse model of type 2 diabetes.
Zhao H; Yakar S; Gavrilova O; Sun H; Zhang Y; Kim H; Setser J; Jou W; LeRoith D
Diabetes; 2004 Nov; 53(11):2901-9. PubMed ID: 15504971
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus.
Pennisi P; Gavrilova O; Setser-Portas J; Jou W; Santopietro S; Clemmons D; Yakar S; LeRoith D
Endocrinology; 2006 Jun; 147(6):2619-30. PubMed ID: 16513827
[TBL] [Abstract][Full Text] [Related]
3. Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling.
Hong EG; Jung DY; Ko HJ; Zhang Z; Ma Z; Jun JY; Kim JH; Sumner AD; Vary TC; Gardner TW; Bronson SK; Kim JK
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1687-96. PubMed ID: 17911348
[TBL] [Abstract][Full Text] [Related]
4. Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes.
Kim H; Haluzik M; Gavrilova O; Yakar S; Portas J; Sun H; Pajvani UB; Scherer PE; LeRoith D
Diabetologia; 2004 Dec; 47(12):2215-25. PubMed ID: 15662559
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis.
Kim H; Haluzik M; Asghar Z; Yau D; Joseph JW; Fernandez AM; Reitman ML; Yakar S; Stannard B; Heron-Milhavet L; Wheeler MB; LeRoith D
Diabetes; 2003 Jul; 52(7):1770-8. PubMed ID: 12829645
[TBL] [Abstract][Full Text] [Related]
6. Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4.
Kim JK; Zisman A; Fillmore JJ; Peroni OD; Kotani K; Perret P; Zong H; Dong J; Kahn CR; Kahn BB; Shulman GI
J Clin Invest; 2001 Jul; 108(1):153-60. PubMed ID: 11435467
[TBL] [Abstract][Full Text] [Related]
7. Muscle-specific overexpression of CD36 reverses the insulin resistance and diabetes of MKR mice.
Héron-Milhavet L; Haluzik M; Yakar S; Gavrilova O; Pack S; Jou WC; Ibrahimi A; Kim H; Hunt D; Yau D; Asghar Z; Joseph J; Wheeler MB; Abumrad NA; LeRoith D
Endocrinology; 2004 Oct; 145(10):4667-76. PubMed ID: 15231693
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein E deficiency abrogates insulin resistance in a mouse model of type 2 diabetes mellitus.
Kawashima Y; Chen J; Sun H; Lann D; Hajjar RJ; Yakar S; Leroith D
Diabetologia; 2009 Jul; 52(7):1434-41. PubMed ID: 19436992
[TBL] [Abstract][Full Text] [Related]
9. Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes.
Toyoshima Y; Gavrilova O; Yakar S; Jou W; Pack S; Asghar Z; Wheeler MB; LeRoith D
Endocrinology; 2005 Sep; 146(9):4024-35. PubMed ID: 15947005
[TBL] [Abstract][Full Text] [Related]
10. Insulin resistance causes increased beta-cell mass but defective glucose-stimulated insulin secretion in a murine model of type 2 diabetes.
Asghar Z; Yau D; Chan F; Leroith D; Chan CB; Wheeler MB
Diabetologia; 2006 Jan; 49(1):90-9. PubMed ID: 16362284
[TBL] [Abstract][Full Text] [Related]
11. Effect of adipocyte beta3-adrenergic receptor activation on the type 2 diabetic MKR mice.
Kim H; Pennisi PA; Gavrilova O; Pack S; Jou W; Setser-Portas J; East-Palmer J; Tang Y; Manganiello VC; Leroith D
Am J Physiol Endocrinol Metab; 2006 Jun; 290(6):E1227-36. PubMed ID: 16682489
[TBL] [Abstract][Full Text] [Related]
12. MKR mice are resistant to the metabolic actions of both insulin and adiponectin: discordance between insulin resistance and adiponectin responsiveness.
Kim CH; Pennisi P; Zhao H; Yakar S; Kaufman JB; Iganaki K; Shiloach J; Scherer PE; Quon MJ; LeRoith D
Am J Physiol Endocrinol Metab; 2006 Aug; 291(2):E298-305. PubMed ID: 16507604
[TBL] [Abstract][Full Text] [Related]
13. Intracerebroventricular leptin infusion improves glucose homeostasis in lean type 2 diabetic MKR mice via hepatic vagal and non-vagal mechanisms.
Li X; Wu X; Camacho R; Schwartz GJ; LeRoith D
PLoS One; 2011 Feb; 6(2):e17058. PubMed ID: 21379576
[TBL] [Abstract][Full Text] [Related]
14. MKR mice have increased dynamic glucose disposal despite metabolic inflexibility, and hepatic and peripheral insulin insensitivity.
Vaitheesvaran B; LeRoith D; Kurland IJ
Diabetologia; 2010 Oct; 53(10):2224-32. PubMed ID: 20577711
[TBL] [Abstract][Full Text] [Related]
15. Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice.
Mosa R; Huang L; Wu Y; Fung C; Mallawakankanamalage O; LeRoith D; Chen C
Endocrinology; 2017 Oct; 158(10):3174-3187. PubMed ID: 28977588
[TBL] [Abstract][Full Text] [Related]
16. Benfluorex normalizes hyperglycemia and reverses hepatic insulin resistance in STZ-induced diabetic rats.
Serradas P; Blondel O; Bailbe D; Portha B
Diabetes; 1993 Apr; 42(4):564-70. PubMed ID: 8454107
[TBL] [Abstract][Full Text] [Related]
17. Ovariectomy is associated with metabolic impairments and enhanced mammary tumor growth in MKR mice.
Ben-Shmuel S; Scheinman EJ; Rashed R; Orr ZS; Gallagher EJ; LeRoith D; Rostoker R
J Endocrinol; 2015 Dec; 227(3):143-151. PubMed ID: 26383532
[TBL] [Abstract][Full Text] [Related]
18. Effect of chronic p,p'-dichlorodiphenyldichloroethylene (DDE) exposure on high fat diet-induced alterations in glucose and lipid metabolism in male C57BL/6H mice.
Howell GE; Mulligan C; Meek E; Chambers JE
Toxicology; 2015 Feb; 328():112-22. PubMed ID: 25541407
[TBL] [Abstract][Full Text] [Related]
19. Primacy of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric moderate-fat diet in the dog.
Kim SP; Ellmerer M; Van Citters GW; Bergman RN
Diabetes; 2003 Oct; 52(10):2453-60. PubMed ID: 14514627
[TBL] [Abstract][Full Text] [Related]
20. Adipose-specific overexpression of GLUT4 reverses insulin resistance and diabetes in mice lacking GLUT4 selectively in muscle.
Carvalho E; Kotani K; Peroni OD; Kahn BB
Am J Physiol Endocrinol Metab; 2005 Oct; 289(4):E551-61. PubMed ID: 15928024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
